HCW Biologics Engages Armistice in Securities Purchase

HCW Biologics ( (HCWB) ) has issued an update.

HCW Biologics Inc. entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd. on May 13, 2025, which included pre-funded warrants for purchasing up to 513,140 shares of common stock. By May 29, 2025, Armistice had exercised warrants to acquire a total of 374,140 shares, leaving 139,000 shares still available for purchase, indicating a significant engagement with Armistice that could impact the company’s financial operations and market positioning.

The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.

Spark’s Take on HCWB Stock

According to Spark, TipRanks’ AI Analyst, HCWB is a Underperform.

HCW Biologics is facing substantial financial challenges, with declining revenues and high leverage being the most significant issues. The technical analysis suggests bearish trends, and the valuation is unattractive due to negative earnings. These factors result in a low overall stock score.

To see Spark’s full report on HCWB stock, click here.

More about HCW Biologics

HCW Biologics Inc. operates in the biotechnology industry, focusing on the development of innovative therapies and products.

Average Trading Volume: 670,168

Technical Sentiment Signal: Sell

Current Market Cap: $19.36M

Learn more about HCWB stock on TipRanks’ Stock Analysis page.